One thing we could say about the analysts on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue estimates were cut sharply as the analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.

We check all companies for important risks. See what we found for ARS Pharmaceuticals in our free report.

Following the downgrade, the consensus from six analysts covering ARS Pharmaceuticals is for revenues of US$71m in 2025, implying a substantial 27% decline in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$83m in 2025. The consensus view seems to have become more pessimistic on ARS Pharmaceuticals, noting the measurable cut to revenue estimates in this update.

Check out our latest analysis for ARS Pharmaceuticals NasdaqGM:SPRY Earnings and Revenue Growth May 15th 2025

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 34% by the end of 2025. This indicates a significant reduction from annual growth of 141% over the last three years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 17% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - ARS Pharmaceuticals is expected to lag the wider industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for ARS Pharmaceuticals this year. They're also anticipating slower revenue growth than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on ARS Pharmaceuticals after today.

Still got questions? At least one of ARS Pharmaceuticals' six analysts has provided estimates out to 2027, which can be seen for free  on our platform here.

Another way to search for interesting companies that could be  reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments